The first prescription of Furmonertinib issued in 15 provinces and municipalities across China
2021/03/09

The first prescription of Furmonertinib issued in 15 provinces and municipalities across China

On March 8th, the day that witnessed the delivery of the first batch of Furmonertinib, the first prescription of this new drug in Beijing, Shanghai and Guangzhou was issued by an array of leading hospitals and doctors including Professor Shi Yuankai at Cancer Hospital of the Chinese Academy of Medical Sciences, Shanghai Chest Hospital, Shanghai Pulmonary Hospital, the First Affiliated Hospital of Guangzhou Medical University, and Sun Yat-sen University Cancer Center. In addition, a total of 12 provinces and municipalities including Zhejiang, Jiangsu, Anhui, Hubei, Hunan, Henan, Inner Mongolia, Shandong, Chongqing, Shanxi, Jiangxi and Liaoning have also given out their first prescription of Furmonertinib, and many of the newly-dispatched drugs have reached the patients with more to follow in other provinces within the coming two days. This speedy delivery of Furmonertinib is a vivid demonstration of the principle of “time is life”.

Ms. Sandy Mu, CEO of Allist, noted that, “there remain large, unmet clinical demands for the treatment of advanced non-small cell lung cancer (NSCLC), which is accompanied by huge needs for high-quality original new drugs. Furmonertinib is an international-standard third generation of EGFR-TKI that has its origin in China. Clinical trials have proven its advantages of bi-functionality, high selectivity, strong effect in tumor regression, and high security. Its anti-tumor effect and safety are especially evident in the treatment of advanced NSCLC metastasized via the central nerve system.” According to her, “with the concept of ‘advancing long life with innovation of science and technology’, staffs at Allist have been striving with all their might and heightened passion to bring tangible benefits to NSCLC patients across China with our Furmonertinib!”

About lung cancer

Lung cancer is a deadly malignant tumor. According to latest data from the International Agency for Research on Cancer (IARC) under the World Health Organization (WHO), China had the largest number of lung cancer cases and deaths in the world in 2020, which stood at 816,000 and 715,000, respectively. Patients with NSCLC account for 85% of the lung cancer patients ; about 50% of patients with lung adenocarcinoma across Asia had epidermal growth factor receptor (EGFR) mutation.

About Furmonertinib

Furmonertinib targets adult patients who have progressed during or after treatment with epidermal growth factor receptor (EGFR) – tyrosine kinase inhibitor (TKI) and diagnosed with EGFR T790M mutation-positive, locally advanced or metastatic NSCLC. Furmonertinib is characterized by its bi-functionality, high selectivity, strong effect in tumor regression, and favorable safety. It is the third generation of EGFR-TKI that China self-developed with independent intellectual property rights.

About Allist

Shanghai Allist Pharmaceuticals Co., Ltd was founded in March, 2004. It is an innovation-oriented drug developer, producer and seller dedicated to oncotherapy that targets the demand of the global pharmaceutical market. With the philosophy of “advancing long life with innovation of science and technology”, its primary mission is to create first-in-class and best-in-class medicines. After 17 years of unremitting efforts, Allist now enjoys comprehensive competitiveness, particularly the ability to develop the best anti-tumor drugs in the market with proved effect, in which it owns independent intellectual property rights.

On December 2, 2020, Shanghai Allist Pharmaceuticals Co., Ltd was listed on the STAR board of Shanghai Stock Exchange (Stock code: 688578).